EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische StudieOpen Access

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study

Tycel Jovelle Phillips iD, Carmelo Carlo-Stella iD, Franck Morschhauser iD, Emmanuel Bachy iD, Michael Crump, Marek Trněný iD, Nancy L Bartlett iD, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, James Relf und 6 weitere

Journal of Clinical Oncology · 20.01.2025 · 43 (3) · 318-328

DOI: 10.1200/jco.23.02470 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2025. Verfasst von Tycel Jovelle Phillips und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor, MI. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lymphoma, Mantle-Cell, Neoplasm Recurrence, Local, Antibodies, Bispecific. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696 ) evaluated glofitamab monotherapy in patients with R/R B-cell lymphomas, with obinutuzumab pretreatment (Gpt) to mitigate the risk of cytokine release syndrome (CRS) with glofitamab. We present data for patients with R/R MCL. METHODS Eligible patients with R/R MCL (at least one previous therapy) received Gpt (1,000 or 2,000 mg) 7 days before the first glofitamab dose (single dose or split over 2 days if required). Glofitamab step-up dosing was administered once a day on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, with a target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles. Efficacy end points included investigator-assessed complete response (CR) rate, overall response rate (ORR), and duration of CR. RESULTS Of 61 enrolled patients, 60 were evaluable for safety and efficacy. Patients had received a median of two previous therapies (range, 1-5). CR rate and ORR were 78.3% (95% CI, 65.8 to 87.9) and 85.0% (95% CI, 73.4 to 92.9), respectively. In patients who had received previous treatment with a Bruton tyrosine kinase inhibitor (n = 31), CR rate was 71.0% (95% CI, 52.0 to 85.8) and ORR was 74.2% (95% CI, 55.4 to 88.1). CRS after glofitamab administration occurred in 70.0% of patients, with a lower incidence in the 2,000 mg (63.6% [grade ≥2, 22.7%]) versus 1,000 mg (87.5%; grade ≥2, 62.5%) Gpt cohort. Four adverse events led to glofitamab withdrawal (all infections). CONCLUSION Fixed-duration glofitamab induced high CR rates in heavily pretreated patients with R/R MCL; the safety profile was manageable with appropriate support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLymphoma, Mantle-CellNeoplasm Recurrence, LocalAntibodies, BispecificAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCytokine Release Syndrome

Substanzen

Antibodies, Monoclonal, HumanizedobinutuzumabglofitamabAntibodies, Bispecific

Autor:innen und Institutionen

  • University of Michigan Medical School, Ann Arbor, MI.
  • Current address: City of Hope National Medical Center, Duarte, CA.
  • Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Milano, Italy.
  • CHU Lille, Service des Maladies du Sang, Lille, France.
  • Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France.
  • Princess Margaret Cancer Centre, Toronto, ON, Canada.

ORCID-Profile: Tycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Marek Trněný, Nancy L Bartlett, Michael Dickinson

Zitieren

APA

Phillips, T. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Crump, M., Trněný, M., Bartlett, N. L., Zaucha, J., Wrobel, T., Offner, F., Humphrey, K., Relf, J., Filézac de L'Etang, A., Carlile, D. J., Byrne, B., Qayum, N., Lundberg, L., & Dickinson, M. (2025). Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of Clinical Oncology, 43(3), 318-328. https://doi.org/10.1200/jco.23.02470

Vancouver

Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trněný M, et al. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of Clinical Oncology. 2025;43(3):318-328. doi:10.1200/jco.23.02470

BibTeX
@article{Phillips2025,
  author = {Phillips, Tycel Jovelle and Carlo-Stella, Carmelo and Morschhauser, Franck and Bachy, Emmanuel and Crump, Michael and Trněný, Marek and Bartlett, Nancy L and Zaucha, Jan and Wrobel, Tomasz and Offner, Fritz and Humphrey, Kathryn and Relf, James and Filézac de L'Etang, Audrey and Carlile, David J and Byrne, Ben and Qayum, Naseer and Lundberg, Linda and Dickinson, Michael},
  title = {Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {3},
  pages = {318--328},
  doi = {10.1200/jco.23.02470}
}
Kostenlos starten →